ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

VAPRISOL
Electrolyte disturbances
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

VAPRISOL Rx

Generic Name and Formulations:
Conivaptan HCl 20mg/100mL in 5% dextrose; soln for IV infusion.

Company:
Cumberland Pharmaceuticals, Inc.

Therapeutic Use:

Indications for VAPRISOL:

Euvolemic and hypervolemic hyponatremia in hospitalized patients.

Limitations Of use:

Not effective for treating signs/symptoms of heart failure.

Adult:

Administer via large veins; rotate infusion site every 24hrs. Loading dose: 20mg IV over 30mins, followed by 20mg continuous IV infusion over 24hrs. After initial day of treatment, give 20mg/day continuous IV infusion for an additional 1–3 days; may titrate up to max 40mg/day if serum sodium is not rising at desired rate. Max duration after loading dose: 4 days. Moderate and severe hepatic impairment: Loading dose: 10mg IV over 30mins, followed by 10mg/day as continuous IV infusion for 2–4 days; may titrate up to max 20mg/day if serum sodium is not rising at desired rate.

Children:

Not established.

Contraindications:

Hypovolemic hyponatremia. Concomitant potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir). Anuric patients.

Warnings/Precautions:

Monitor serum sodium concentration, volume status, neurologic status. Discontinue if serum sodium rises too rapidly (>12mEq/L per 24hrs); may resume at reduced dose if hyponatremia persists or recurs and no evidence of neurologic sequelae. Discontinue if hypovolemia or hypotension develops; frequently monitor volume status and vital signs; may resume at reduced dose if euvolemic and not hypotensive. Severe renal impairment: not recommended. Pregnancy. Nursing mothers: not recommended.

Interactions:

See Contraindications. Potentiated by CYP3A4 inhibitors. Potentiates CYP3A4 substrates (eg, midazolam, simvastatin, amlodipine); avoid; allow at least 1 week after end of conivaptan administration before resuming these drugs. May potentiate digoxin; monitor.

Pharmacological Class:

Dual arginine vasopressin (V1A and V2) receptors antagonist.

Adverse Reactions:

Infusion site reactions (eg, phlebitis, erythema, pain), GI upset, headache, hypokalemia, hyponatremia, orthostatic hypotension, hyper- or hypotension, peripheral edema, thirst, pyrexia.

How Supplied:

Single-use premixed soln—1

Sign Up for Free e-newsletters